Replacement of the Human Topoisomerase Linker Domain with the Plasmodial Counterpart Renders the Enzyme Camptothecin Resistant

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Arnò, Barbara ^a   D'Annessa, Ilda ^a   Tesauro, Cinzia ^a   Zuccaro, Laura ^a   Ottaviani, Alessio ^a   Knudsen, Birgitta ^b   Fiorani, Paola ^c   Desideri, Alessandro ^a  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b AARHUS UNIVERSITY   (Denmark)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; HYBRID PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STRUCTURE; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PROTEIN DOMAIN;

BINDING SITES; BIOCATALYSIS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DNA, SUPERHELICAL; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PLASMODIUM FALCIPARUM; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TOPOISOMERASE I INHIBITORS;

PLASMODIUM FALCIPARUM;

EID: 84879757291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068404     Document Type: Article

References (54)

1. Champoux JJ, (2001) DNA topoisomerase I-mediated nicking of circular duplex DNA. Methods Mol Biol 95: 81-87. PubMed: 11089222.
2. Wang JC, (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3: 430-440. doi:10.1038/nrm831. PubMed: 12042765.
3. Corbett KD, Berger JM, (2004) Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 33: 95-118. doi:10.1146/annurev.biophys.33.110502.140357. PubMed: 15139806.
4. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802. doi:10.1038/nrc1977. PubMed: 16990856.
5. Stewart L, Ireton GC, Parker LH, Madden KR, Champoux JJ, (1996) Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 271: 7593-7601. doi:10.1074/jbc.271.13.7593. PubMed: 8631793.
6. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG, (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504-1513. doi:10.1126/science.279.5356.1504. PubMed: 9488644.
7. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ, (1998) A model for the mechanism of human topoisomerase I. Science 279: 1534-1541. doi:10.1126/science.279.5356.1534. PubMed: 9488652.
8. Koster DA, Croquette V, Dekker C, Shuman S, Dekker NH, (2005) Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature 434: 671-674. doi:10.1038/nature03395. PubMed: 15800630.
9. Castelli S, Coletta A, D'Annessa I, Fiorani P, Tesauro C, et al. (2012) Interaction between natural compounds and human topoisomerase I. Biol Chem 393: 1327-1340. PubMed: 23109546.
10. Pommier Y, (2009) DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 109: 2894-2902. doi:10.1021/cr900097c. PubMed: 19476377.
11. Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, et al. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 48: 2336-2345. doi:10.1021/jm049146p. PubMed: 15801827.
12. Stewart L, Ireton GC, Champoux JJ, (1999) A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J Biol Chem 274: 32950-32960. doi:10.1074/jbc.274.46.32950. PubMed: 10551862.
13. Chillemi G, Redinbo M, Bruselles A, Desideri A, (2004) Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics. Biophys J 87: 4087-4097. doi:10.1529/biophysj.104.044925. PubMed: 15347588.
14. Redinbo MR, Stewart L, Champoux JJ, Hol WG, (1999) Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. J Mol Biol 292: 685-696. doi:10.1006/jmbi.1999.3065. PubMed: 10497031.
15. Chillemi G, Castrignano T, Desideri A, (2001) Structure and hydration of the DNA-human topoisomerase I covalent complex. Biophys J 81: 490-500. doi:10.1016/S0006-3495(01)75716-5. PubMed: 11423431.
16. Fiorani P, Bruselles A, Falconi M, Chillemi G, Desideri A, et al. (2003) Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J Biol Chem 278: 43268-43275. doi:10.1074/jbc.M303899200. PubMed: 12904303.
17. Scaldaferro S, Tinelli S, Borgnetto ME, Azzini A, Capranico G, (2001) Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I. Chem Biol 8: 871-881. doi:10.1016/S1074-5521(01)00059-X. PubMed: 11564555.
18. D'Annessa I, Tesauro C, Fiorani P, Chillemi G, Castelli S, et al. (2012) Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin. J Amino Acids: pp. 2012: 206083.
19. Mancini G, D'Annessa I, Coletta A, Sanna N, Chillemi G, et al. (2010) Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I- DNA complex. PLOS ONE 5: e10934. doi:10.1371/journal.pone.0010934. PubMed: 20532182.
20. Mancini G, D'Annessa I, Coletta A, Chillemi G, Pommier Y, Cushman M, Desideri A, (2012) Binding of an indenoisoquinoline to the topoisomerase-DNA complex induces reduction of linker mobility and strengthening of protein-DNA interaction. PLOS ONE (In press).
21. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr., et al. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 99: 15387-15392. doi:10.1073/pnas.242259599. PubMed: 12426403.
22. Chillemi G, Fiorani P, Castelli S, Bruselles A, Benedetti P, et al. (2005) Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study. Nucleic Acids Res 33: 3339-3350. doi:10.1093/nar/gki642. PubMed: 15944452.
23. Fiorani P, Tesauro C, Mancini G, Chillemi G, D'Annessa I, et al. (2009) Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. Nucleic Acids Res 37: 6849-6858. doi:10.1093/nar/gkp669. PubMed: 19767617.
24. Chillemi G, D'Annessa I, Fiorani P, Losasso C, Benedetti P, et al. (2008) Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. Nucleic Acids Res 36: 5645-5651. doi:10.1093/nar/gkn558. PubMed: 18765473.
25. Losasso C, Cretaio E, Fiorani P, D'Annessa I, Chillemi G, et al. (2008) A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance. Nucleic Acids Res 36: 5635-5644. doi:10.1093/nar/gkn557. PubMed: 18772225.
26. van der Merwe M, Bjornsti MA, (2008) Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin. J Biol Chem 283: 3305-3315. PubMed: 18056711.
27. Szklarczyk O, Staron K, Cieplak M, (2009) Native state dynamics and mechanical properties of human topoisomerase I within a structure-based coarse-grained model. Proteins 77: 420-431. doi:10.1002/prot.22450. PubMed: 19452556.
28. Sari L, Andricioaei I, (2005) Rotation of DNA around intact strand in human topoisomerase I implies distinct mechanisms for positive and negative supercoil relaxation. Nucleic Acids Res 33: 6621-6634. doi:10.1093/nar/gki935. PubMed: 16314322.
29. Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti MA, et al. (2007) Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality. J Biol Chem 282: 9855-9864. doi:10.1074/jbc.M608200200. PubMed: 17276985.
30. Frohlich RF, Juul S, Nielsen MB, Vinther M, Veigaard C, et al. (2008) Identification of a minimal functional linker in human topoisomerase I by domain swapping with Cre recombinase. Biochemistry 47: 7127-7136. doi:10.1021/bi800031k. PubMed: 18553933.
31. Garcia-Estrada C, Prada CF, Fernandez-Rubio C, Rojo-Vazquez F, Balana-Fouce R, (2010) DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery. Proc Biol Sci 277: 1777-1787. doi:10.1098/rspb.2009.2176. PubMed: 20200034.
32. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC, (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49: 6318-6323. PubMed: 2553253.
33. Kauh EA, Bjornsti MA, (1995) SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc Natl Acad Sci U S A 92: 6299-6303. doi:10.1073/pnas.92.14.6299. PubMed: 7603986.
34. Juul S, Nielsen CJ, Labouriau R, Roy A, Tesauro C, et al. (2012) Droplet Microfluidics Platform for Highly Sensitive and Quantitative Detection of Malaria-Causing Plasmodium Parasites Based on Enzyme Activity Measurement. ACS Nano.
35. Andersen AH, Gocke E, Bonven BJ, Nielsen OF, Westergaard O, (1985) Topoisomerase I has a strong binding preference for a conserved hexadecameric sequence in the promoter region of the rRNA gene from Tetrahymena pyriformis. Nucleic Acids Res 13: 1543-1557. doi:10.1093/nar/13.5.1543. PubMed: 2987828.
36. Yang Z, Champoux JJ, (2002) Reconstitution of enzymatic activity by the association of the cap and catalytic domains of human topoisomerase I. J Biol Chem 277: 30815-30823. doi:10.1074/jbc.M205302200. PubMed: 12077150.
37. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410. doi:10.1016/S0022-2836(05)80360-2. PubMed: 2231712.
38. Notredame C, Higgins DG, Heringa J, (2000) T-Coffee: A novel method for fast and accurate multiple sequence alignment. J Mol Biol 302: 205-217. doi:10.1006/jmbi.2000.4042. PubMed: 10964570.
39. Schwede T, Kopp J, Guex N, Peitsch MC, (2003) SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 31: 3381-3385. doi:10.1093/nar/gkg520. PubMed: 12824332.
40. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201. doi:10.1093/bioinformatics/bti770. PubMed: 16301204.
41. Powell MJD, (1964) An Efficient Method for Finding the Minimum of a Function of Several Variables without Calculating Derivatives Comput J 17: 155-162.
42. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723. doi:10.1002/elps.1150181505. PubMed: 9504803.
43. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24: 1999-2012. doi:10.1002/jcc.10349. PubMed: 14531054.
44. Hess B, Kutzner C, van der Spoel D, Lindahl E, (2008) GROMACS 4: algorithm for highly Efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4: 435-447.
45. Sorin EJ, Pande VS, (2005) Exploring the helix-coil transition via all-atom equilibrium ensemble simulations. Biophys J 88: 2472-2493. doi:10.1529/biophysj.104.051938. PubMed: 15665128.
46. Jorgensen WL, Chandrasekhar J, Madura JD, Impery RW, Klein ML, (1983) Comparison of simple potential functions for simulating liquid water J Chem Phys 79: 926-935. doi:10.1063/1.445869.
47. Cheatham TE, Miller JL, Fox T, Darden TA, Kollman PA, (1995) Molecular-Dynamics Simulations on Solvated Biomolecular Systems- the Particle Mesh Ewald Method Leads to Stable Trajectories of DNA, Rna, and Proteins. J Am Chem Soc 117: 4193-4194. doi:10.1021/ja00119a045.
48. Ryckaert JP, Ciccotti G, Berendsen HJC, (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J Comput Phys 23: 327-341. doi:10.1016/0021-9991(77)90098-5.
49. Berendsen HJC, Pstma JPM, van Gusteren WF, Di Nola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath J Comput Phys 81: 3684-3690.
50. Parrinello M, Rahman A, (1981) Polymorphic Transitions in Single-Crystals- a New Molecular-Dynamics Method. Appl Phys 52: 7182-7190. doi:10.1063/1.328693.
51. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 1433-38,: 27-38.
52. Liu LF, (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375. doi:10.1146/annurev.bi.58.070189.002031. PubMed: 2549853.
53. Lisby M, Krogh BO, Boege F, Westergaard O, Knudsen BR, (1998) Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis. Biochemistry 37: 10815-10827. doi:10.1021/bi980757r. PubMed: 9692972.
54. Kim N, Huang SN, Williams JS, Li YC, Clark AB, et al. (2011) Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science 332: 1561-1564. doi:10.1126/science.1205016. PubMed: 21700875.